| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = -$36,497 ) |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG069701 | Biology and pathobiology of apoE in aging and Alzheimer's disease | 000 | 5 | NIH | 12/11/2025 | $0 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA279916 | Deiminated molecules as markers for developing pancreatic cancer - A1 | 000 | 2 | NIH | 10/21/2025 | $0 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01GM144393 | Exploiting new approaches for selective inhibition of trypsins | 000 | 4 | NIH | 10/27/2025 | $0 |
| | 2026 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA237602 | Involution-based biomarkers of breast cancer risk | 000 | 5 | NIH | 11/21/2025 | -$36,497 |
|
| Issue Date FY: 2025 ( Subtotal = $55,836,381 ) (Continued on the next page) |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA279916 | Deiminated molecules as markers for developing pancreatic cancer - A1 | 001 | 2 | NIH | 6/2/2025 | $21,949 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01HL169268 | Individualized medicine to predict and prevent chemotherapy-related heart failure | 000 | 3 | NIH | 7/24/2025 | $641,876 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01HL164520 | Role of mitochondrial extracellular vesicles in CVB3 myocarditis by sex | 000 | 4 | NIH | 7/4/2025 | $721,646 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01HL140411 | Distinct Pathways of VPF/VEGF Receptors | 000 | 6 | NIH | 7/23/2025 | $653,379 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R13CA290996 | Science of Community Outreach and Engagement (SoCOE) Conference | 000 | 2 | NIH | 7/10/2025 | $10,000 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS129671 | Tumor targeted drug delivery nanoplatform to overcome therapy resistance glioblastoma | 000 | 3 | NIH | 12/13/2024 | $556,541 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01NS136022 | Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS (SEA-NOBI-ALS) | 001 | 2 | NIH | 9/5/2025 | $5,712,981 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS137907 | Targeting Signaling Between Glioblastoma and the Subventricular Zone Niche | 000 | 2 | NIH | 8/5/2025 | $434,922 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS132330 | Investigating the role of TMEM106b genetics and pathology in Alzheimer’s disease, LATE and FTLD | 000 | 3 | NIH | 8/26/2025 | $1,060,236 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F30AG085984 | The Role of TMEM106B in FTLD-TDP Pathogenesis | 000 | 2 | NIH | 11/15/2024 | $49,174 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F30AG085984 | The Role of TMEM106B in FTLD-TDP Pathogenesis | 001 | 2 | NIH | 6/23/2025 | $564 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG077656 | Accelerated Resolution Therapy for Early Maladaptive Grief: A Clinical Trial | 001 | 3 | NIH | 6/17/2025 | $52,690 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG077656 | Accelerated Resolution Therapy for Early Maladaptive Grief: A Clinical Trial | 000 | 3 | NIH | 3/6/2025 | $592,775 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG054199 | APOE and microglia-mediated progression in tau pathology in AD | 001 | 4 | NIH | 8/11/2025 | $721,020 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG075802 | Investigating regional and cellular vulnerabilities to tau pathology in young-onset Alzheimer's disease | 001 | 4 | NIH | 8/11/2025 | $239,814 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG075802 | Investigating regional and cellular vulnerabilities to tau pathology in young-onset Alzheimer's disease | 000 | 4 | NIH | 12/6/2024 | $2,697,909 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA276313 | A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer | 000 | 3 | NIH | 6/26/2025 | $639,109 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | UH3AG083186 | Mayo Advancing Research Engagement in ADRD Study (MAREAS Jax) | 000 | 3 | NIH | 9/16/2025 | $1,133,766 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG084236 | ACTS (AD Clinical Trial Simulation): Developing Advanced Informatics Approaches for an Alzheimer's Disease Clinical Trial Simulation System | 003 | 3 | NIH | 7/14/2025 | $973,545 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA266113 | Disease Progression Modeling of Bladder Cancer | 000 | 3 | NIH | 7/10/2025 | $497,514 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG078615 | Discovery of apoE4 modulators for Alzheimer’s disease therapy | 001 | 4 | NIH | 6/18/2025 | $33,995 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG078615 | Discovery of apoE4 modulators for Alzheimer’s disease therapy | 000 | 4 | NIH | 4/9/2025 | $382,444 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS121075 | Metabolic interactions between tumor cells and the immune system in GBM: A potential Achilles heel of GBM for novel therapeutics | 001 | 4 | NIH | 7/3/2025 | $366,265 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS121125 | Frontotemporal dementia and related disorders: transcriptomic profiling, biomarker discovery, and mechanistic insight | 000 | 5 | NIH | 7/17/2025 | $780,935 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01CA274970 | A Multi-level Approach to Connecting Individuals to Cancer Clinical Research | 002 | 5 | NIH | 9/18/2025 | $223,681 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01CA274970 | A Multi-level Approach to Connecting Individuals to Cancer Clinical Research | 001 | 5 | NIH | 8/18/2025 | $470,401 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | K23DK131338 | Approaches and Outcomes of Shared Decision-making and Patient Centered Care Delivery in Barrett's Esophagus | 003 | 4 | NIH | 5/14/2025 | $199,171 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01GM144393 | Exploiting new approaches for selective inhibition of trypsins | 001 | 4 | NIH | 9/9/2025 | -$263,805 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01GM144393 | Exploiting new approaches for selective inhibition of trypsins | 001 | 4 | NIH | 9/9/2025 | $293,116 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01GM144393 | Exploiting new approaches for selective inhibition of trypsins | 000 | 4 | NIH | 11/14/2024 | $263,805 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA255068 | PRSS1 Mutation and Pancreatic Cancer Tumorigenesis | 001 | 5 | NIH | 9/3/2025 | $850,552 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG069701 | Biology and pathobiology of apoE in aging and Alzheimer's disease | 000 | 5 | NIH | 6/18/2025 | $6,293,390 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG072719 | Assessment of a novel tau propagation pathway from layer II medial entorhinal cortical neurons to CA1 pyramidal neurons as an early Braak stage mouse model | 001 | 5 | NIH | 6/13/2025 | $42,632 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG072719 | Assessment of a novel tau propagation pathway from layer II medial entorhinal cortical neurons to CA1 pyramidal neurons as an early Braak stage mouse model | 000 | 5 | NIH | 4/3/2025 | $479,602 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA258274 | Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy | 002 | 5 | NIH | 9/16/2025 | $32,250 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA258274 | Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy | 001 | 5 | NIH | 2/14/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA258274 | Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy | 000 | 5 | NIH | 1/22/2025 | $290,242 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS117461 | Poly(ADP-ribose) promotes the condensation and toxicity of C9orf72 arginine-rich dipeptide repeat proteins | 000 | 4 | NIH | 7/11/2025 | $480,550 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS117461 | Poly(ADP-ribose) promotes the condensation and toxicity of C9orf72 arginine-rich dipeptide repeat proteins | 000 | 4 | NIH | 7/11/2025 | $101,935 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG067763 | Molecular characterization of extracellular vesicles for the spread of misfolded tau protein | 001 | 5 | NIH | 6/13/2025 | $48,912 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG067763 | Molecular characterization of extracellular vesicles for the spread of misfolded tau protein | 000 | 5 | NIH | 4/4/2025 | $550,252 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01NS119169 | Long-Term Observational Extension of Participants in the CREST-2 Randomized Clinical Trial | 001 | 5 | NIH | 9/12/2025 | $740,873 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA239726 | A Genetically Tractable Mouse Model for PRKCI-driven Lung Squamous Cell Carcinoma | 000 | 5 | NIH | 7/2/2025 | $284,301 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS123052 | C9orf72-mediated features transcriptomic signatures and translational studies for frontotemporal dementia and related disorders | 000 | 2 | NIH | 7/4/2025 | $788,248 |
|
